Phase I Investigation of the Feasibility of Combining 5-azacytidine With Highdose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy in a Sequential Manner for Remission Induction in High-risk Acute Myelogenous Leukemia (AML)
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Jan 2018
Price : $35 *
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Cytarabine (Primary) ; Mitoxantrone (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Biomarker; Pharmacogenomic
- 31 Aug 2018 Biomarkers information updated
- 02 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Sep 2018.
- 02 Jan 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Sep 2018.